MARKET

CNSP

CNSP

CNS Pharmaceuticals
NASDAQ
3.120
+0.410
+15.13%
Pre Market: 3.130 +0.01 +0.32% 06:24 03/17 EDT
OPEN
2.810
PREV CLOSE
2.710
HIGH
3.350
LOW
2.730
VOLUME
1.18K
TURNOVER
--
52 WEEK HIGH
1,195.00
52 WEEK LOW
2.000
MARKET CAP
4.68M
P/E (TTM)
-0.0008
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CNSP last week (0303-0307)?
Weekly Report · 03/10 12:33
Weekly Report: what happened at CNSP last week (0224-0228)?
Weekly Report · 03/03 12:32
CNS Pharmaceuticals jumps on current cash position update
Seeking Alpha · 02/26 14:53
CNS Pharmaceuticals reports cash position of $14M as of February 26
TipRanks · 02/26 14:20
Weekly Report: what happened at CNSP last week (0217-0221)?
Weekly Report · 02/24 12:32
CNS Pharmaceuticals Inc trading halted, news pending
TipRanks · 02/21 00:50
S&P 500 Edges Higher; Analog Devices Earnings Top Views
Benzinga · 02/19 18:29
Dow Dips 150 Points; US Housing Starts Fall In January
Benzinga · 02/19 15:36
More
About CNSP
CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system (CNS). The Company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is in development for the treatment of a number of serious brain and CNS oncology indications, including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. In addition, the Company is advancing the development of its WP1244/WP1874 drug technology, which utilizes anthracycline and distamycin-based scaffolds to create small molecule agents. The Company is also evaluating the use of WP1244/WP1874 in the treatment of other primary brain and central nervous system cancers, as well as cancers metastatic to the brain including pancreatic, ovarian, and lymphomas.

Webull offers CNS Pharmaceuticals Inc stock information, including NASDAQ: CNSP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CNSP stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CNSP stock methods without spending real money on the virtual paper trading platform.